Eli Lilly: FDA accepts to review migraine drug.
(CercleFinance.com) - Eli Lilly said that the US Food and Drug Administration has accepted to review a submission of a new drug application for the prevention of migraine in adults.
Galcanezumab has been submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe, Lilly said on Monday in a statement.
On Friday the US drugmaker said a Phase 3 study on Cyramza in the treatment of patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma met its primary endpoint of progression-free survival, but did not improve overall survival, a secondary endpoint.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Galcanezumab has been submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe, Lilly said on Monday in a statement.
On Friday the US drugmaker said a Phase 3 study on Cyramza in the treatment of patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma met its primary endpoint of progression-free survival, but did not improve overall survival, a secondary endpoint.
Copyright (c) 2017 CercleFinance.com. All rights reserved.